Ind-Swift Laboratories Limited has informed the Exchange about Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ind-Swift Laboratories' investment committee has approved investing up to Rs. 95 Crores in Optionally Convertible Redeemable Preference Shares (OCRPS) of Khandelwal Finance Private Ltd (KFPL), a Kolkata-based registered NBFC and part of the SAI Group. The investment involves subscribing to 5,60,800 OCRPS at Rs. 1,694 each, carrying an 8.25% non-cumulative dividend, a 5-year tenor, and a 2-year lock-in. The OCRPS can either be redeemed at issue price or fair market value (whichever is higher) or converted into equity shares of KFPL. KFPL is not related to Ind-Swift's promoters or group companies, and the transaction is not a related-party deal. Ind-Swift will also get a board observer seat, information rights, inspection rights, and pre-emptive rights.
This is a treasury/capital deployment decision into a financial instrument rather than a core pharma expansion. Short-term impact on stock is likely neutral, though it indicates the company has surplus cash to deploy. Investors should monitor the redemption/conversion outcome after 5 years for actual returns.